Navigation Links
Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand Ability to Treat Brain and Spinal Tumors
Date:8/7/2008

Installation at Burdenko Institute of Neurosurgery will be Accuray's Second

in Russia

SUNNYVALE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the Burdenko Institute of Neurosurgery in Moscow has purchased a CyberKnife(R) Robotic Radiosurgery System. When the system is installed, the Burdenko Institute will become the second facility in Russia to offer advanced robotic radiosurgery treatments.

The CyberKnife System will enable the Burdenko Institute to expand its ability to treat tumors and other diseases of the brain and spine. With real-time image guidance and the ability to adjust for patient and tumor movement during treatment, clinicians are able to deliver radiation with extreme precision without requiring patients to be positioned in uncomfortable frames. Because it is non-invasive and does not require the use of frames, the CyberKnife System is ideal for those users who wish to deliver fractionated intracranial treatments.

"The Burdenko Institute is world renowned for its expertise in the treatment of neurological conditions," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "With the addition of a CyberKnife System, clinicians there will be able to expand their radiosurgical capabilities, while offering patients a viable, non-invasive alternative to traditional surgery."

Established in 1932 as the Moscow Institute of Neurosurgery the facility focused specifically on neurosurgery. The institute was later renamed for Nikolai Nilovich Burdenko, who is regarded as the founder of Russian neurosurgery. The Burdenko Institute currently is led by Alexander N. Konovalov, M.D., Ph.D., who has served as its director for more than 32 years and is one of the foremost figures in Russian neurosurgery.

The Burdenko Institute will receive its CyberKnife System by the end of the 2008 calendar year through local distributor Newstep Ltd.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2007 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
4. Leading-edge body sensor could help produce sporting champions
5. Hospital Quality Info on Web Can Be Misleading
6. AT&T Establishes New Network Services for Leading Medical Liability Insurer
7. Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nations Preparedness for Disasters
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
10. Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert
11. Long Term Care Insurance Gains Momentum Thanks to State Promotions, a Leading Brokerage Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... ... Center is now offering various types of dental implants to restore lost teeth. Dental implants ... such as crowns, bridges, or dentures. An implant is placed directly into the jawbone where ... tooth. , Several types of dental implants are available, including: , ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for ... the hiring of Richard Robinson as chief operating officer (COO). In this role, ... a proven track record of simplifying business processes and developing growth strategies to ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with ... Angela Cotey, with or without a referral. Dr. Cotey is a trusted dentist who ... preferred tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: